Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: Thomson Reuters StreetEvents
$75.00
Provider: GlobalData
$250.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

FDA Advisory Committee Recommends Approval of Medivir AB's Simeprevir for Combination Treatment of Genotype 1 Chronic Hepatitis C in Adult Patients


Thursday, 24 Oct 2013 04:10pm EDT 

Medivir AB announced that the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted 19 to 0 to recommend approval of the investigational protease inhibitor simeprevir (TMC435) 150 mg capsules administered once daily with pegylated interferon and ribavirin for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease, including cirrhosis. The Advisory Committee recommended the approval of simeprevir based on analyses of data from clinical trials in patients who are treatment-na├»ve or who have failed previous interferon-based therapy. 

Company Quote

124.5
0.25 +0.20%
6:30am EDT